Literature DB >> 24927263

Targeted therapies for treatment of recurrent ovarian cancer.

Rachel N Grisham1, David M Hyman1, Gopa Iyer1.   

Abstract

Ovarian cancer remains the leading cause of death among women with gynecologic malignancies in the United States. Most women with epithelial ovarian cancer present with advanced disease. Despite good response rates to initial surgery and chemotherapy, the majority of patients experience relapse and ultimately die of their disease. A better understanding of the molecular differences underlying the histologic subtypes of epithelial ovarian cancer has led to recent advances in targeted therapeutic strategies. Here we review the most promising targeted therapeutics currently being used for the treatment of recurrent ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24927263

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  7 in total

1.  Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.

Authors:  Kibeom Jang; Hyunho Yoon; Karina E Hew; Fiona Simpkins; Minsoon Kim; Diana J Azzam; Jun Sun; Dekuang Zhao; Tan A Ince; Wenbin Liu; Wei Guo; Zhi Wei; Gao Zhang; Gordon B Mills; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2018-06-29       Impact factor: 12.531

2.  Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

Authors:  Rachel N Grisham; Kathleen N Moore; Michael S Gordon; Wael Harb; Gwendolyn Cody; Darragh F Halpenny; Vicky Makker; Carol A Aghajanian
Journal:  Clin Cancer Res       Date:  2018-05-29       Impact factor: 12.531

3.  Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family.

Authors:  Ciyu Yang; Angela G Arnold; Magan Trottier; Yukio Sonoda; Nadeem R Abu-Rustum; Oliver Zivanovic; Mark E Robson; Zsofia K Stadler; Michael F Walsh; David M Hyman; Kenneth Offit; Liying Zhang
Journal:  Breast Cancer Res Treat       Date:  2016-10-18       Impact factor: 4.872

4.  Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.

Authors:  Jinyou Liu; Suryavathi Viswanadhapalli; Lauren Garcia; Mei Zhou; Binoj C Nair; Edward Kost; Rajeshwar Rao Tekmal; Rong Li; Manjeet K Rao; Tyler Curiel; Ratna K Vadlamudi; Gangadhara R Sareddy
Journal:  Oncotarget       Date:  2017-07-25

5.  miR-423-5p serves as a diagnostic indicator and inhibits the proliferation and invasion of ovarian cancer.

Authors:  Xuebiao Tang; Xiaogang Zeng; Yu Huang; Shibing Chen; Fang Lin; Ge Yang; Nian Yang
Journal:  Exp Ther Med       Date:  2018-04-02       Impact factor: 2.447

6.  A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma.

Authors:  Yuchen Zhang; Lina Zhu; Xin Wang
Journal:  Genes (Basel)       Date:  2020-02-01       Impact factor: 4.096

7.  Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.

Authors:  Bai Xue; Shupeng Li; Xianyu Jin; Lifeng Liu
Journal:  BMC Cancer       Date:  2021-04-23       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.